Home Newsfeeds Wedbush Downgrades Applied Genetic Techs to Neutral

Wedbush Downgrades Applied Genetic Techs to Neutral

Wedbush analyst David Nierengarten downgrades Applied Genetic Techs (NASDAQ:AGTC) from Outperform to Neutral.

byBenzinga Newsdesk

October 24, 2022

1 minute read

Wedbush analyst David Nierengarten downgrades Applied Genetic Techs (NASDAQ:AGTC) from Outperform to Neutral.

Schwazze’s Q1 2024 Financial Results: Takes A Hit In Colorado, Overall Cannabis Sales Up By 9%

By Nicolas Jose Rodriguez

May 15, 6:14 PM

Medicine Man Technologies, Inc., operating as Schwazze (OTC: SHWZ), announced its financial results for the first quarter ended March 31, 2024.

SHWZ

Apple’s India-Made iPhone Exports Surpass $2.5B In 9 Months — Nearly Twice Previous Fiscal Year’s Total

By Navdeep Yadav

January 9, 7:50 AM

Apple Inc. (NASDAQ:AAPL) exported more than $2.5 billion worth of iPhones from India between April and December as…

AAPL

Cybin’s Novel Psilocybin Topline Data: 79% Remission In Major Depression Symptoms, What’s Next?

By Lara Goldstein

December 3, 9:42 PM

Next-generation psychedelics biotech Cybin Inc. (NYSE: CYBN) released the full Phase 2 trial results of its deuterated psilocybin derivative CYB003 for Major Depressive Disorder (MDD.) Although a relatively small trial, outcomes for the novel psychedelic are so far showing st

CYBN

$100 Invested In This Stock 10 Years Ago Would Be Worth $400 Today

By Benzinga Insights

February 2, 5:34 PM

Illinois Tool Works (NYSE:ITW) has outperformed the market over the past 10 years by 4.26% on an annualized…

ITW

Wedbush Downgrades Applied Genetic Techs to Neutral

Related Posts

Schwazze’s Q1 2024 Financial Results: Takes A Hit In Colorado, Overall Cannabis Sales Up By 9%

Apple’s India-Made iPhone Exports Surpass $2.5B In 9 Months — Nearly Twice Previous Fiscal Year’s Total

Cybin’s Novel Psilocybin Topline Data: 79% Remission In Major Depression Symptoms, What’s Next?

$100 Invested In This Stock 10 Years Ago Would Be Worth $400 Today